ENVB
Enveric Biosciences, Inc.
There isn't enough reported data to score ENVB yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ENVB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ENVB's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENVB PE Valuation
ENVB has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ENVB Forward outlook
There aren't enough analyst estimates for ENVB to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ENVB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.55 | +$109.18 |
| Q1 2026 | -$36.43 | +$131.66 |
| Q4 2025 | -$49.99 | +$213.26 |
| Q3 2025 | -$102.34 | +$354.86 |
| Q2 2025 | -$134.73 | +$513.27 |
| Q1 2025 | -$168.09 | +$982.11 |
| Q4 2024 | -$263.25 | +$1,192.95 |
| Q3 2024 | -$457.20 | +$2,305.80 |
ENVB lost $25.55 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ENVB on earnings quality, reporting a profit while its opponent remains loss making.
ENVB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2020 | $8.5M | -7.3% |
LLY has the edge over ENVB in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2020 | -13% | +3.9 points |
| Q2 2020 | -14% | N/A |
| Q1 2020 | -17% | N/A |
| Q4 2019 | -22% | N/A |
| Q3 2019 | -17% | N/A |
ENVB's operating margin was −13% last quarter, up 3.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ENVB in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ENVB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.4M | -$554.4K |
| Q1 2026 | -$2.3M | +$134.7K |
| Q4 2023 | -$1.8M | +$1.7M |
| Q3 2023 | -$2.7M | +$1.8M |
| Q2 2023 | -$4.5M | +$173.1K |
| Q1 2023 | -$5.1M | -$87.7K |
| Q4 2022 | -$3.5M | +$599K |
| Q3 2022 | -$4.6M | -$2.4M |
ENVB has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ENVB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ENVB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +164% | +2.5M shares |
| 1 year | +1743% | +3.8M shares |
| 3 years | +33951% | +4M shares |
| 5 years | +623857% | +4M shares |
| Available history | +6645040% | +4M shares |
ENVB has 4M diluted shares, up 1743% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ENVB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ENVB Net Leverage
ENVB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ENVB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.3 | Neutral |
| Stochastic | 53.9 | Neutral |
ENVB's weekly RSI is 41 (neutral) and its Stochastic is 54 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ENVB PE vs Healthcare Sector
ENVB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ENVB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.45 | 4.8% above |
| 20 week MA | $1.45 | 4.8% above |
| 50 week MA | $2.33 | 35% below |
| 100 week MA | $11.2 | 86% below |
| 200 week MA | $141.9 | 99% below |
ENVB has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 99% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ENVB on trend strength, trading above more of its moving averages.
ENVB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $86,400.0 | $60,840.0 | -30% |
| 2021 | $60,840.0 | $9,630.0 | -84% |
| 2022 | $9,630.0 | $316.8 | -97% |
| 2023 | $316.8 | $234.0 | -26% |
| 2024 | $234.0 | $62.5 | -73% |
| 2025 | $62.5 | $4.11 | -93% |
| 2026 YTD | $4.11 | $1.52 | -63% |
ENVB has finished every year since 2020 lower, and it's down 63% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ENVB on returns for 2026, with the stronger performance.